Anidulafungin: Advantage for the newcomer?

Expert Review of Clinical Pharmacology

Volumn 1, Issue 2, 2008, Pages 207-216

  Rüping, Maria J ^a   Vehreschild, Jörg J ^a   Farowski, Fedja ^a   Cornely, Oliver A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Anidulafungin; Antifungal agents; Aspergillosis; Candidiasis; Drug therapy; Echinocandins; Invasive fungal infection; Therapeutic use

Indexed keywords

1,3 BETA GLUCAN SYNTHASE; AMPHOTERICIN B; ANIDULAFUNGIN; BETA 1,3 GLUCAN; CASPOFUNGIN; CORTISONE ACETATE; CYCLOSPORIN A; EFAVIRENZ; FLUCONAZOLE; MICAFUNGIN; NEVIRAPINE; RAVUCONAZOLE; RIFAMPICIN; TACROLIMUS; VORICONAZOLE;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CANDIDA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ESOPHAGUS CANDIDIASIS; FEBRILE NEUTROPENIA; FLUSHING; FUNGICIDAL ACTIVITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; INJECTION SITE REACTION; INVASIVE CANDIDIASIS; LIVER DYSFUNCTION; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MYCOSIS; NAUSEA; NONHUMAN; OROPHARYNX CANDIDIASIS; PHARMACODYNAMICS; SIDE EFFECT; SINGLE DRUG DOSE; VERTIGO;

EID: 49249095910     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.2.207     Document Type: Article

References (75)

1. Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 86(8), 862-870 (2001).
2. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine 79(4), 250-260 (2000).
3. Chen S, Slavin M, Nguyen Q et al. Active surveillance for candidemia, Australia. Emerging Infect. Dis. 12(10), 1508-1516 (2006).
4. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. 32(3), 358-366 (2001).
5. Wenzel RP. Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. 20(6), 1531-1534 (1995).
6. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39(3), 309-317 (2004).
7. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44(4), 531-540 (2007).
8. Pagano L, Caira M, Picardi M et al. Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality - SEIFEM-C Report. Clin. Infect. Dis. 44(11), 1524-1525 (2007).
9. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45(6), 1735-1745 (2007).
10. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis. 29(6), 1402-1407 (1999).
11. Bates DW, Su L, Yu DT et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int. 60(4), 1452-1459 (2001).
12. Ullmann AJ, Sanz MA, Tramarin A et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin. Infect. Dis. 43(4), E29-E38 (2006).
13. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin. Infect. Dis. 33(9), 1529-1535 (2001).
14. Villanueva A, Gotuzzo E, Arathoon EG et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. J. Med. 113(4), 294-299 (2002).
15. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. 46(2), 451-457 (2002).
16. Kartsonis NA, Saah A, Lipka CJ, Taylor A, Sable CA. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study. J. Antimicrob. Chemother. 53(5), 878-881 (2004).
17. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347(25), 2020-2029 (2002).
18. Maertens J, Glasmacher A, Herbrecht R et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 107(12), 2888-2897 (2006).
19. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351(14), 1391-1402 (2004).
20. van Burik JA, Ratanatharathorn V, Stepan DE et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39(10), 1407-1416 (2004).
21. de Wet NT, Bester AJ, Viljoen JJ et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment. Pharmacol. Ther. 21(7), 899-907 (2005).
22. Krause DS, Simjee AE, van Rensburg C et al. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin. Infect. Dis. 39(6), 770-775 (2004).
23. Reboli AC, Rotstein C, Pappas PG et al. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356(24), 2472-2482 (2007).
24. Final package insert ERAXIS™ (anidulafungin). For injection.
25. Barrett D. From natural products to clinically useful antifungals. Biochim. Biophys. Acta 1587(2-3), 224-233 (2002).
26. Douglas CM, Foor F, Marrinan JA et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc. Natl Acad. Sci. USA 91(26), 12907-12911 (1994).
27. Kahn JN, Garcia-Effron G, Hsu MJ, Park S, Marr KA, Perlin DS. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51(5), 1876-1878 (2007).
28. Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57(4), 705-708 (2006).
29. Pfaller MA, Boyken L, Hollis RJ, Messer SA. Tendolkar S, Diekema DJ. In vitro activities of Anidulafungin against more than 2,500 clinical solates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43(11), 5425-5427 (2005).
30. Messer SA, Kirby JT, Sader HS, Fritsche TR, Jones RN. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 54(6), 1051-1056 (2004).
31. Marco F, Danes C, Almela M et al. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). Diagn. Microbiol. Infect. Dis. 46(4), 259-264 (2003).
32. Arevalo MP, Carrillo-Munoz AJ, Salgado J et al. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Cbemother. 51(1), 163-166 (2003).
33. Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP. In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob. Agents Chemother. 50(11), 3926-3928 (2006).
34. Insa R, Peláez T, Goyanes M et al. In vitro activity of anidulafungin and caspofungin in Candida species: there is a significant correlation between the activity of both Candins? Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 17-20 September 2006 (Abstract M-1592).
35. Nagappan V, Riederer K, Big C, Vazquez JA. In vitro activity of echinocandins against different strains of Candida parapsilosis. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 17-20 September 2006 (Abstract M-1581).
36. Bernhardt H, Knoke M, Schwesinger G et al. Effects of voriconazole (VCZ) and anidulafungin (ANID) on flow culture biofilms of C. glabrata (Cg) and C. parapsilosis (Cp). Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007 (Abstract M-1845).
37. Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Cbemother. 51(6), 2257-2259 (2007).
38. Serrano Mdel C, Valverde-Conde A, Chavez MM et al. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against Aspergidus spp. Diagn. Microbiol. Infect. Dis. 45(2), 131-135 (2003).
39. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36(10), 2950-2956 (1998).
40. Oakley KL, Moore CB, Denning DW. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob. Agents Chemother. 42(10), 2726-2730 (1998).
41. Bartlett MS, Current WL, Goheen MP et al. Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo. Antimicrob. Agents Chemother. 40(8), 1811-1816 (1996).
42. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30(4), 251-255 (1998).
43. Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. 48(5), 1912-1915 (2004).
44. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50(7), 2522-2524 (2006).
45. Groll AH, Mickiene D, Petraitiene R et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob. Agents Chemother. 45(10), 2845-2855 (2001).
46. Clemons KV, Sobel RA, Stevens DA. Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids. Antimicrob. Agents Chemother. 44(2), 378-381 (2000).
47. Dowell JA, Pu F, Lee J, Stogniew M, Krause D, Henkel T. A clinical mass balance study of Anidulafungin (ANID) showing complete fecal elimination. Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 14-17 September 2003 (Abstract A-1576 and poster).
48. Petraitiene R, Petraitis V, Groll AH et al. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits. Antimicrob. Agents Chemother. 43(9), 2148-2155 (1999).
49. Ostrosky-Zeichner L, Paetznick VL, Rodriguez J, Chen E, Sheehan DJ. Activity of Anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and serum β glucan levels. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007 (Abstract M-1840).
50. Gumbo T, Drusano GL, Liu W et al. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis. Antimicrob. Agents Chemother. 50(11), 3695-3700 (2006).
51. Wiederhold NP, Najvar LK, Bocanegra R, Molina D, Olivo M, Graybill JR. In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera. Antimicrob. Agents Chemother. 51(5), 1616-1620 (2007).
52. Petraitis V, Petraitiene R, Groll AH et al. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 45(2), 471-479 (2001).
53. Verweij PE, Oakley KL, Morrissey J, Morrissey G, Denning DW. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42(4), 873-878 (1998).
54. Roberts J, Schock K, Marino S, Andriole VT. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY303366, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 44(12), 3381-3388 (2000).
55. Petraitis V, Petraitiene R, Groll AH et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42(11), 2898-2905 (1998).
56. Petraitis V, Petratiene R, Hope W et al. Combination therapy of voriconazole and Anidulafungin improves outcome of experimental pulmonary aspergillosis. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. USA, 17-20 September 2006 (Abstract M882).
57. Brown GL, White RJ, Taubd J. Phase I dose optimization study for V-echinocandin. Presented at: Interscience Coorence on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada, 17-20 September 2000 (Poster 1105).
58. Thye D, Shepherd B, White RJ, Weston HE, Henkel I. Anidulafiingin: a Phase I study to identify the maximum tolerated dose in healthy volunteers. Presented at: Interscience Conference on Andmicrabial Agents and Chemotherapy Chicago, IL, USA, 16-19 December 2001 (Abstract A36).
59. Stogniew M, Pu F, Henkel T, Dowell J. Anidulafungin biotransformation in humans is by degradation not metabolism. Clin. Microbiol. Infect. 9(Suppl.), 291 (2003).
60. Kelley K, Chapman S, Cleary J. Digestion of echinocandins. Presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, 17-20 September 2006.
61. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. Comparative in vitro pharmacodynamics of echinocandins against Aspergillus germinated and nongerminated conidia1 Presented at: 47th Interscience Conference on Antmicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007 (Abstract M1820).
62. Dowell JA, Stogniew M, Krause D, Darrile B. Anidulaffingin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J. Clin. Pharmacol. 47(4), 461-470 (2007).
63. Benjamin DK Jr, Driscoll T, Seibel NL et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob. Agents Cbemother. 50(2), 632-638 (2006).
64. Dowell JA, Stogniew M, Krause D, Henkel T, Damle B. Lack of pharmacokinetic interaction between anidulafungin and tacrolimus. J. Clin. Pharmacol. 47(3), 305-314 (2007).
65. Dowell JA, Schranz J, Baruch A, Foster G. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J. Clin. Pharmacol. 45(12), 1373-1382 (2005).
66. Dowell JA, Schranz J, Stogniew M, Krause D, Henkel T. Assessment of the pharmacokinetics of anidulafungin in patients with invasive aspergillosis receiving concomitant liposomal amphotericin. Presented at: European Congress of Clinical Microbiology and Infectious Diseases. Prague, Czech Republic 1-4 May 2004.
67. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 44(6), 590-598 (2004).
68. Dowell JA, Stogniew M, Krause D, Henkel T, Weston IE. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J. Clin. Pharmacol. 45(2), 227-233 (2005).
69. Krause D S, Reinhardt J, Vazquez JA et al. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48(6), 2021-2024 (2004).
70. Brummer E, Chauhan SD, Stevens DA. Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus. J. Antimicrob. Chemother. 43(4), 491-496 (1999).
71. Pfaller MA, Diekema DJ, Boyken L et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob. Agents Chemother. 49(11), 4795-4797 (2005).
72. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20, 121-136 (2003).
73. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J. Clin. Microbiol. 40(3), 852-856 (2002).
74. Earnshaw SR, Graham CN, Gasper SM. Cost effectiveness of anidulafungin therapy in confirmed candidemia and other forms of invasive candidiasis. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA, 17-20 September 2007 (Abstract O-1867).
75. Sobel JD, Revankar SG. Echinocandins - first-choice or first-line therapy for invasive candidiasis? N. Engl. J. Med. 356(24), 2525-2526 (2007).